Ignet

Gene Information

Gene symbol: STN

Gene name: statin

HGNC ID: 11416

Related Genes

#	Gene Symbol	Number of hits
1	ABCG8	1 hits
2	ACE	1 hits
3	ADIPOQ	1 hits
4	AGT	1 hits
5	ALB	1 hits
6	APOA1	1 hits
7	APOB	1 hits
8	APOM	1 hits
9	CCL2	1 hits
10	CETP	1 hits
11	CRP	1 hits
12	CYBB	1 hits
13	CYP2C9	1 hits
14	IL10	1 hits
15	IL6	1 hits
16	INS	1 hits
17	LPL	1 hits
18	MPO	1 hits
19	NOX5	1 hits
20	NPHS1	1 hits
21	PCSK9	1 hits
22	PECAM1	1 hits
23	PON1	1 hits
24	PPARA	1 hits
25	PPARG	1 hits
26	PRKAA1	1 hits
27	RETN	1 hits
28	TNF	1 hits
29	TNFRSF11B	1 hits

Related Sentences

#	PMID	Sentence
1	21855068	We examined the associations between statin use and C-reactive protein (CRP), tumour necrosis factor ? (TNF-?), interleukin-1? (IL-1?) and interleukin-6 (IL-6) in a healthy Caucasian population.
2	11799261	To determine whether cerivastatin, a newly developed novel synthetic potent statin, exerts a renoprotective effect, we assessed urinary albumin excretion (UAE) and plasma and urinary endothelin (ET)-1 concentrations in normotensive microalbuminuric type 2 diabetes patients with dyslipidemia.
3	12663600	In conclusion, the B1B1/CC carriers of the CETP polymorphisms have a more atherogenic lipid profile, including low HDL, and they respond better to statin therapy.
4	12663600	These results favor the hypothesis that CETP polymorphisms modify the effect of statin treatment and may help to identify patients who will benefit most from statin therapy.
5	15262189	Since low LPL activity indicates an increased cardiovascular risk, the statin-mediated increase in LPL activity may help to explain the reduction of CAD in diabetic patients treated with statins.
6	16290992	Similar patterns were observed in stratified analyses based on sex, statin use, and diabetes status: weak but negative association of CAC with CRP, which became nonsignificant with adjustment for covariates.
7	16412224	Statin treated patients showed significantly lower epicardial expression of IL-6 mRNA, in comparison with the control abdominal depots (p < 0.001).
8	16518588	In diabetic patients statin therapy is associated with reduced MTTP expression and increased ABCG5 and ABCG8 mRNA.
9	16629852	Defining the therapeutic target of statin therapy in terms of serum apolipoprotein B (apo B) rather than LDL cholesterol could also help to optimize statin treatment.
10	17054594	The negative association between CACS and CRP remained in multivariate analysis, and was independent of statin use.
11	17699218	Patients with MPO activity greater than the median had significantly (P < 0.05) lower serum albumin levels (33.2 +/- 0.7 versus 35.0 +/- 0.5 g/L), higher 8-hydroxydeoxyguanosine levels (1.26 +/- 0.08 versus 1.05 +/- 0.06 ng/ml), and a lower prevalence of statin treatment (18 versus 36%).
12	17699218	This cross-sectional study suggests that both diabetes and statin treatment affect MPO activity in prevalent HD patients.
13	17376428	Thus, direct modulation of adipocyte function may represent a mechanism of pleiotropic statin actions.
14	17764005	Insulin level and brain infarcts were associated with more severe WML and statin use with less severe WML (all p < 0.05).
15	17785630	Higher plasma resistin levels were associated with a higher urine albumin:creatinine ratio in black subjects with diabetes (P<0.0001) and non-Hispanic white subjects with diabetes (P=0.032), independent of coronary heart disease risk factors, hypertension medication use, and statin use; the association remained significant after additional adjustment for homeostasis model assessment for insulin resistance and C-reactive protein.
16	18316203	Additionally, the statin augmented breaking strength and PECAM-1 immunostaining at day 12.
17	19208914	To test the hypotheses that decreased insulin-mediated glucose disposal in muscle is associated with a reduced muscle microvascular exchange capacity (Kf) and that 6 months of high-dose statin therapy would improve microvascular function in people with central obesity.
18	19449750	Although there has been disappointment with the first cholesteryl-ester-transfer-protein-inhibitor, there is encouraging evidence that increasing HDL with the peroxisome-proliferator-activator-receptor (PPAR) gamma agonist, pioglitazone and nicotinic acid derivatives may contribute beyond statin therapy.
19	19505224	The extent to which statin therapy affects relationships of LDL-C and non-HDL-C with apoB was examined in type 2 diabetes.
20	19748621	The pattern of low HDL cholesterol, low apolipoprotein A1, small LDL particles, and high triglycerides drives vascular risk in statin-treated coronary patients, particularly in those with T2DM.
21	20207952	There were no differences for patients with variants of CYP2C9, CYP2C19, or SLCO1B1 in comparison with their respective wild types, nor were differential effects on statin response seen for patients with the most common genotypes for CYP3A5 and BCRP (n=415; odds ratio: 1.207; 95% CI: 0.768, 1.899; P=0.415).
22	18378570	Statin treatment also prevents diabetes-induced increases in expression of the NADPH oxidase catalytic and subunit NOX2.
23	20649626	Fenofibrate concomitantly decreased serum PCSK9 and VLDL particle concentrations in statin-treated T2DM patients.
24	20573750	FA with or without statin also reduced non-HDL cholesterol, apolipoprotein B, total cholesterol, VLDL cholesterol, and high-sensitivity C-reactive protein.
25	20619837	Here, we determined how standard dose of statin and combined therapy with fenofibrate modulate PCSK9.
26	20950383	Across the pooled study sample, change in ambulatory activity was significantly correlated with change in interleukin-6 (r = -0.32, P = 0.01) after adjustment for group, age, sex, ethnicity, aspirin and statin medication, baseline body mass index and change in body mass index.
27	20719975	Here we assessed the effects of maximal RAS inhibition by angiotensin-converting enzyme (ACE) inhibitor plus angiotensin II type 1 receptor blocker (ARB) in combination with statin in rats with overt diabetic nephropathy.
28	20719975	Defective nephrin expression of diabetes was increased by dual RAS blockade or statin and restored by the triple therapy.
29	20876207	Statin-induced changes in its level may be important in decreasing apoB glycation in diabetes.
30	20828695	Here, we determined whether plasma apoM is affected by statin or fibrate administration in patients with diabetes mellitus.
31	15585763	After adjustment for age, sex, body mass index, diabetes, smoking, ejection fraction, New York Heart Association class, ischemic etiology, statin use, and serum glucose, TFA levels were positively associated with interleukin (IL) 1beta (difference from mean: 0.38 pg/mL; percentage difference from mean: 66%; P=0.04), IL-1 receptor antagonist (4033 pg/mL; 297%; P=0.006), IL-6 (9.5 pg/mL; 123%; P=0.006), IL-10 (241 pg/mL; 183%; P=0.02), tumor necrosis factor (TNF) alpha (256 pg/mL; 249%; P=0.02), TNF receptor 1 (537 pg/mL; 41%; P=0.03), TNF receptor 2 (39 242 pg/mL; 247%; P=0.001), monocyte chemoattractant protein 1 (117 pg/mL; 119%; P=0.004), and brain natriuretic peptide (40 pg/mL; 57%; P=0.04).
32	21216833	Our primary goal was to determine whether OPG provided independent prognostic information in patients with chronic HF, and to examine its potential interactions with statin therapy.
33	20299472	Likewise, AMPK activation by pharmacological (5'-aminoimidazole-4-carboxymide-1-beta-d-ribofuranoside, metformin, and statin) or genetic means (adenoviral overexpression of constitutively active AMPK mutants) significantly mitigated ER stress and SERCA oxidation and improved the endothelium-dependent relaxation in isolated mouse aortae.
34	21376415	For vascular protection, 55.1% were on a statin, 72.1% on an ACE inhibitor or ARB, and 64.5% on an anticoagulant.
35	21231776	Multiple linear regression analysis showed that LL genotype for PON1 (p < 0.03), high body mass index (BMI) values (p < 0.001) and low HDL-cholesterol levels (p < 0.05) are associated with high C-reactive protein levels independently from presence of stress-induced ischemia, age, sex, diabetes, hypertension, statin therapy, smoking and total cholesterol levels.